نتایج جستجو برای: ژن pik3ca

تعداد نتایج: 18195  

2017
Shi-Yuan Liu Wei Chen Ehtesham Annait Chughtai Zhe Qiao Jian-Tao Jiang Shao-Min Li Wei Zhang Jin Zhang

AIM To evaluate PIK3CA gene mutational status in Northwest Chinese esophageal squamous cell carcinoma (ESCC) patients, and examine the associations of PIK3CA gene mutations with clinicopathological characteristics and clinical outcome. METHODS A total of 210 patients with ESCC who underwent curative resection were enrolled in this study. Pyrosequencing was applied to investigate mutations in ...

2015
Seung Tae Kim Maruja Lira Shibing Deng Sujin Lee Young Suk Park Ho Yeong Lim Won Ki Kang Mao Mao Jin Seok Heo Wooil Kwon Kee-Taek Jang Jeeyun Lee Joon Oh Park

PIK3CA mutation is considered a good candidate for targeted therapies in cancers, especially biliary tract cancer (BTC). We evaluated the utility of cell free DNA (cfDNA) from serum by using droplet digital PCR (ddPCR) as an alternative source for PIK3CA mutation analysis. To identify matching archival tumour specimens from serum samples of advanced BTC patients, mutation detection using ddPCR ...

2017
Ji-Won Kim Hye Seung Lee Kyung Han Nam Soyeon Ahn Jin Won Kim Sang-Hoon Ahn Do Joong Park Hyung-Ho Kim Keun-Wook Lee

PIK3CA mutations are frequent in gastric cancer. However, their pathological and clinical implications are still unclear. We analyzed the clinicopathological characteristics according to the PIK3CA mutation status of patients with stage IB-IV disease who underwent gastrectomy between May 2003 and Dec. 2005 (cohort 1; n = 302) and of those with stage IV disease who received gastrectomy between J...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2010
Sherene Loi Benjamin Haibe-Kains Samira Majjaj Francoise Lallemand Virginie Durbecq Denis Larsimont Ana M Gonzalez-Angulo Lajos Pusztai W Fraser Symmans Alberto Bardelli Paul Ellis Andrew N J Tutt Cheryl E Gillett Bryan T Hennessy Gordon B Mills Wayne A Phillips Martine J Piccart Terence P Speed Grant A McArthur Christos Sotiriou

PIK3CA mutations are reported to be present in approximately 25% of breast cancer (BC), particularly the estrogen receptor-positive (ER+) and HER2-overexpressing (HER2+) subtypes, making them one of the most common genetic aberrations in BC. In experimental models, these mutations have been shown to activate AKT and induce oncogenic transformation, and hence these lesions have been hypothesized...

2015
Gilles Manceau Laetitia Marisa Valérie Boige Alex Duval Marie-Pierre Gaub Gérard Milano Janick Selves Sylviane Olschwang Valérie Jooste Michè le Legrain Delphine Lecorre Dominique Guenot Marie-Christine Etienne-Grimaldi Sylvain Kirzin Laurent Martin Come Lepage Anne-Marie Bouvier Pierre Laurent-Puig

PIK3CA, which encodes the p110α catalytic subunit of PI3Kα, is one of the most frequently altered oncogenes in colon cancer (CC), but its prognostic value is still a matter of debate. Few reports have addressed the association between PIK3CA mutations and survival and their results are controversial. In the present study, we aimed to clarify the prognostic impact of PIK3CA mutations in stage I-...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Hua Yuan Jiuan Chen Yiqiang Liu Tao Ouyang Jinfeng Li Tianfeng Wang Zhaoqing Fan Tie Fan Benyao Lin Yuntao Xie

PURPOSE The association between PIK3CA mutations and response to neoadjuvant chemotherapy in women with primary breast cancer is not fully elucidated. EXPERIMENTAL DESIGN PIK3CA mutations in breast cancer tissues that were taken prior to the initiation of neoadjuvant chemotherapy were identified in 729 operable primary breast cancer patients who received neoadjuvant chemotherapy. Among these,...

2013
Ariella B. Hanker Rebecca S. Cook Carlos L. Arteaga

Approximately one in four breast cancers is driven by amplification of the receptor tyrosine kinase HER2 (ERBB2). HER2 signals through oncogenic pathways, such as the phosphatidylinositol-3-kinase (PI3K)-Akt pathway. Blockade of HER2 with FDA-approved drugs such as trastuzumab, lapatinib, and pertuzumab has changed the natural history of HER2-positive (HER2+) breast cancers and improved patient...

2016
Zhengbo Song Xinmin Yu Yiping Zhang

PIK3CA mutation represents a clinical subset of diverse carcinomas. We explored the status of PIK3CA mutation and evaluated its genetic variability, treatment, and prognosis in patients with lung adenocarcinoma. A total of 810 patients with completely resected lung adenocarcinoma were recruited between 2008 and 2013. The status of PIK3CA mutation and other three genes, that is, EGFR mutation, K...

2016
Si-Hyong Jang Kyung-Ju Kim Mee-Hye Oh Ji-Hye Lee Hyun Ju Lee Hyun Deuk Cho Sun Wook Han Myoung Won Son Moon Soo Lee

PURPOSE PIK3CA is often mutated in a variety of malignancies, including colon, gastric, ovary, breast, and brain tumors. We investigated PIK3CA expression in gastric cancer and explored the relationships between the PIK3CA expression level and clinicopathological features as well as survival of the patients. MATERIALS AND METHODS We examined PIK3CA expression in a tissue microarray of 178 gas...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Youji He Laura J Van't Veer Izabela Mikolajewska-Hanclich Marie-Louise F van Velthuysen Eliane C M Zeestraten Iris D Nagtegaal Cornelis J H van de Velde Corrie A M Marijnen

PURPOSE Identifying rectal cancer patients at risk for local recurrence would allow for refinement in the selection of patients who would benefit from preoperative radiotherapy. PIK3CA, KRAS, and BRAF mutations are commonly found in colon cancers, but their prevalence has not been clearly assessed in rectal cancer. In this study, we aim to determine the mutation frequencies of PIK3CA, KRAS, and...

200420052006200720082009201020112012201320142015201620172018201920202021202220230400800

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید